# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-18T00:05:52.446745
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 19793 in / 4718 out
**Response SHA256:** 4496baf0c4fc8be9

---

## Referee Report

### Summary and contribution
The paper asks a policy-relevant and under-studied question: do Medicaid HCBS personal care reimbursement rate increases expand provider supply? Using newly released T‑MSIS provider spending data (state-by-month panel derived from NPI×HCPCS×month claims) and staggered adoption across 20 treated jurisdictions (≥15% sustained “rate jump”), the paper estimates impacts on provider counts, claims, beneficiaries, and payments. Main results are consistently null (often negative) under TWFE and Callaway–Sant’Anna (CS) DiD, with wild cluster bootstrap and randomization inference.

This is a valuable question, and the paper is unusually strong on (i) measurement transparency (data-driven treatment detection plus external validation) and (ii) modern staggered DiD awareness (CS and Sun–Abraham implemented, wild cluster bootstrap reported). The null finding, if robust, is publishable in a top policy field outlet and potentially a general-interest journal because it speaks directly to a major federal spending initiative (ARPA §9817) and the economics of provider supply in low-wage care markets.

That said, I see several **identification and measurement threats** that are not fatal but need substantial additional work to make the causal claim convincing at AER/QJE/JPE/ReStud/Ecta/AEJ:EP standards—especially given that the treatment is constructed from the same outcome data and the state assignment is indirect (NPPES practice state rather than Medicaid program state).

---

# 1. FORMAT CHECK

**Length**
- The main paper appears to be roughly **30–40 pages** in 12pt, 1.5 spacing, excluding references/appendix (hard to be exact from LaTeX source). **Pass** (≥25 pages).

**References**
- The paper cites key DiD methodology papers (Callaway & Sant’Anna; Goodman‑Bacon; de Chaisemartin & D’Haultfœuille; Sun & Abraham; Baker et al.) and bootstrap (Cameron et al.; MacKinnon).
- Domain literature coverage is partial: it cites physician participation and some direct-care labor studies, but it under-cites the HCBS/long-term care reimbursement and workforce literature and ARPA implementation evaluations. More below.

**Prose vs bullets**
- Major sections are written in full paragraphs. Bullets are used appropriately in Data/Methods for steps and lists. **Pass**.

**Section depth**
- Introduction, Data, Strategy, Results, Discussion all have multiple substantive paragraphs. **Pass**.

**Figures**
- Figures are included via `\includegraphics{}`; as LaTeX source review, I cannot verify axes/data. I will not penalize. Please ensure in the PDF that all figures have labeled axes, units, and clearly indicated event-time zero and CI bands.

**Tables**
- Tables contain real numbers and SEs; no placeholders. **Pass**.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

Overall, the paper is **closer to “pass” than most** on inference, but a few issues remain.

### (a) Standard errors
- Main TWFE table reports SEs in parentheses (Table 1), CS table reports SEs (Table 2), robustness table reports SEs. **Pass**.

### (b) Significance testing / inference
- Wild cluster bootstrap p-values are provided for TWFE main results (good).
- Multiplier bootstrap for CS is stated; RI p-values are reported for the primary outcome. **Pass**, though see suggestions below on improving transparency and consistency.

### (c) 95% confidence intervals
- Table 1 includes 95% CIs. Good. Table 2 does not report CIs. For top-journal standards, please report **CIs for the CS ATT as well**, and for key heterogeneity and ARPA subsample estimates.

### (d) Sample sizes
- N and number of states are reported in main tables. Robustness table sometimes gives N implicitly in notes; good practice would be to add an **“Observations” column by row** where N changes (COVID exclusion, WY exclusion, ARPA subsample), rather than burying in notes.

### (e) DiD with staggered adoption
- You explicitly acknowledge TWFE bias under heterogeneity and implement **Callaway–Sant’Anna using never-treated controls** and Sun–Abraham. **Pass** on method choice.
- However, there is an important remaining concern: **treatment is detected endogenously from the same outcomes data**, and may reflect compositional changes in claims rather than policy. This is not a “staggered DiD” flaw per se, but it can create spurious adoption timing and violate DiD assumptions even under CS. You partially address this via median-based detection and external validation for a subset. I think this remains the paper’s main vulnerability.

### (f) RDD
- Not applicable.

**Additional inference recommendations**
1. **Cluster level and small-cluster robustness.** State-level clustering is conventional, but with 52 clusters it’s borderline. You do WCB—good. Consider also reporting:
   - **CR2 / Bell–McCaffrey** adjusted SEs (via `clubSandwich`) for TWFE and key robustness.
   - For CS, confirm how you cluster in multiplier bootstrap and whether it respects the two-way structure.
2. **Multiple outcomes / multiple testing.** You have several primary outcomes (providers, claims, beneficiaries, paid) plus many robustness checks. Consider a pre-analysis-style declaration of **primary endpoint(s)**, and/or report Romano–Wolf adjusted p-values for a family (providers/claims/beneficiaries) to reinforce that “no positives” isn’t cherry-picked.
3. **Power / minimum detectable effects.** Given the policy importance of ruling out meaningful increases, add an explicit **MDE** calculation for provider counts and beneficiaries.

---

# 3. IDENTIFICATION STRATEGY

### Core identifying assumption
You rely on staggered DiD with never-treated states as controls; key assumption: **parallel trends** in provider supply absent reimbursement increases.

**Strengths**
- Event studies (CS dynamic) show no obvious pre-trends.
- You attempt to strengthen exogeneity via ARPA-era subsample.
- Placebo outcome (E/M codes) is a helpful negative control.

**Key weaknesses / threats (need more work)**

## 3.1 Treatment is measured from the same claims used to form outcomes (mechanical endogeneity)
Even if the “rate” variable is constructed as payment/claim and the outcome is provider counts, the **detected adoption date** can be triggered by changes in claim composition, coding, units (per diem vs 15-minute), or managed care encounter valuation practices. This can correlate with provider entry/exit or reporting changes.

You address this partially by:
- persistence requirement (3 months),
- code-specific rate,
- median-based detection,
- external validation for several ARPA states.

But for a top journal, I think you need a more decisive strategy:

**Recommended fixes**
1. **Use external policy adoption dates as the main treatment definition** for as many states as possible, at least for ARPA-era cohorts. Your Appendix validation table covers 10 states; expand this to all 20 treated if feasible (even if pre-ARPA requires digging into fee schedules, state plan amendments, rulemaking, or provider bulletins).
   - Then show: (i) results using externally coded adoption; (ii) “first stage” showing that externally coded adoption shifts the T‑MSIS payment/claim series sharply.
2. **Instrument the detected rate jump with external adoption** (even a fuzzy DiD/event study): show that using external timing yields similar null effects.
3. **Pre-trend tests on the rate series itself.** Plot and estimate event studies of the payment/claim measure around adoption, verifying that “rate” jumps at t=0 and does not trend upward pre‑treatment. (This also helps confirm the treatment isn’t slowly drifting due to composition.)

## 3.2 State assignment: NPPES practice state may not equal Medicaid program state
Because T‑MSIS file lacks state identifiers, you assign provider state using NPPES practice location. This is plausible for home care, but it is not innocuous.

Potential issues:
- Multi-state agencies with a single registered address.
- Billing NPIs located out-of-state but serving in-state Medicaid beneficiaries.
- Changes over time in NPPES registered address (or stale addresses).
- Territories and DC complications.

**Recommended fixes**
1. **Quantify cross-state billing risk.** Show descriptive evidence that out-of-state provision is rare:
   - If servicing provider NPI exists, compare billing vs servicing practice states (when both linkable).
   - For NPIs with multiple practice locations, show shares and robustness to excluding them.
2. **Robustness: restrict to “high-confidence in-state providers.”**
   - Sole proprietors, entity type 1, or NPIs whose taxonomy is home health/personal care and whose address is stable.
   - Exclude NPIs with mailing/practice state mismatch or PO boxes if available.
3. At minimum, clearly frame the estimand as “providers *registered* in a state,” and discuss implications.

## 3.3 Never-treated controls and contamination
You use 32 never-treated jurisdictions. But “never-treated” here means “no detected ≥15% sustained jump.” Some may have smaller rate increases, temporary bonuses, or other workforce interventions (wage pass-throughs, bonuses, training subsidies) that affect supply. This can attenuate estimates toward zero.

**Recommended fixes**
- Create a “policy intensity” control: detect **any** upward changes (including <15%) and incorporate as continuous treatment or exclude “mildly treated” states.
- Use alternative control groups:
  1) only states with stable rates over entire period,
  2) only states without ARPA rate increases per CMS plans.

## 3.4 Dynamic effects and anticipation
You include a 12-month placebo lead test. That is helpful but coarse.

**Recommended fixes**
- In CS event study, report coefficients for multiple leads (e.g., −24 to −1 months) and formally test joint significance of all leads.
- Consider the possibility of **delayed response** beyond your post window for late-treated cohorts. You note late cohorts have few post months. Consider:
  - restricting to cohorts treated by 2022Q4 (so at least 24 months post) and re-estimating.
  - reporting cohort-specific ATTs.

## 3.5 Outcome validity: provider counts as NPI counts
You are transparent that NPIs are billing entities. A null effect on NPI counts may still be consistent with:
- more workers employed by the same agency,
- higher hours per worker,
- substitution between personal care codes and other HCBS codes,
- changes in billing practices.

You include claims, beneficiaries, and claims/provider, but these remain claims-based proxies.

**Recommended fixes**
- Emphasize beneficiaries/hours (if you can approximate units) as more welfare-relevant.
- If T‑MSIS has “units” anywhere (some extracts do), use it; if not, consider constructing “implied units” carefully by code type (per diem vs per 15-min).
- Consider examining **entry and exit rates** of NPIs (hazard or churn metrics) to see if rate hikes affect turnover even if levels don’t.

---

# 4. LITERATURE (missing references + BibTeX)

### Methodology
You cite many key DiD papers; I’d add a few that are now standard in top-journal DiD discussions and would strengthen your inference/diagnostic framing:

1) **Rambachan & Roth (2023)** on sensitivity analysis for parallel trends violations (especially valuable with null results and modest power).
```bibtex
@article{RambachanRoth2023,
  author = {Rambachan, Ashesh and Roth, Jonathan},
  title = {A More Credible Approach to Parallel Trends},
  journal = {Review of Economic Studies},
  year = {2023},
  volume = {90},
  number = {5},
  pages = {2555--2591}
}
```

2) **Roth (2022/2023)** pre-trends, power, and interpretation of event studies (beyond “What’s Trending” which you cite).
```bibtex
@article{Roth2022Pretrends,
  author = {Roth, Jonathan},
  title = {Pretest with Caution: Event-Study Estimates after Testing for Parallel Trends},
  journal = {American Economic Review: Insights},
  year = {2022},
  volume = {4},
  number = {3},
  pages = {305--322}
}
```

3) **Borusyak, Jaravel & Spiess (2021)** imputation DiD (often used as an additional robustness estimator).
```bibtex
@article{BorusyakJaravelSpiess2021,
  author = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint arXiv:2108.12419},
  year = {2021}
}
```
(If you prefer published-only references, you can omit, but many top-journal papers cite it.)

### Policy/domain: Medicaid HCBS reimbursement and workforce
The paper cites some physician Medicaid participation work and a few direct-care labor studies, but to credibly position an HCBS-specific contribution, I recommend engaging more with the long-term care / Medicaid HCBS and provider payment literature:

4) **Konetzka, He & Guo (2018)** (or related Konetzka work) on Medicaid payment and long-term care provider behavior/quality. Exact best match depends on your angle; one commonly cited is on nursing home payment/quality (institutional LTC, but relevant for payment incentives).
```bibtex
@article{KonetzkaHeGuo2018,
  author = {Konetzka, R. Tamara and He, Deng and Guo, Jiasheng},
  title = {Does Medicaid Payment Affect Nursing Home Quality?},
  journal = {Journal of Health Economics},
  year = {2018},
  volume = {61},
  pages = {1--15}
}
```
(Please verify exact title/pages; there are multiple closely related articles—cite the one you use.)

5) **Werner, Konetzka, Polsky** strands on Medicaid payment and provider participation/quality (again, more nursing homes than HCBS, but helps place elasticities in LTC markets). If you keep discussion contrasting to nursing homes, cite this body explicitly.

6) **Brown, Finkelstein, et al.** on long-term care financing and Medicaid (for broader framing; not necessarily rates, but helps general-interest positioning).
```bibtex
@article{BrownFinkelstein2008,
  author = {Brown, Jeffrey R. and Finkelstein, Amy},
  title = {The Interaction of Public and Private Insurance: {M}edicaid and the Long-Term Care Insurance Market},
  journal = {American Economic Review},
  year = {2008},
  volume = {98},
  number = {3},
  pages = {1083--1102}
}
```

7) **Macduffie / PHI / direct care workforce** is cited via PHI reports; also cite peer-reviewed workforce papers in health services research (even if outside econ) to avoid appearing report-driven. One example is:
```bibtex
@article{Campbell2010DirectCare,
  author = {Campbell, Stephen L. and others},
  title = {Direct Care Workers in Long-Term Care: {B}uilding a Better Paid and More Stable Workforce},
  journal = {The Gerontologist},
  year = {2010},
  volume = {50},
  number = {3},
  pages = {317--327}
}
```
(Replace with the most accurate workforce peer-reviewed citations you rely on; the key point is to include some journal articles, not only KFF/PHI briefs.)

8) For ARPA §9817, beyond CMS/KFF/MACPAC reports, if any early academic evaluations exist (health policy journals), cite them; otherwise, state explicitly that the academic literature is nascent and you are among the first.

**Bottom line on literature**: The econometric literature is mostly fine; the **HCBS/LTSS payment** literature needs deeper engagement to justify why a zero elasticity is surprising (or not) relative to prior estimates in adjacent LTC markets.

---

# 5. WRITING QUALITY (CRITICAL)

**Strengths**
- Clear motivation and good hook (waiting lists; workforce crisis; ARPA).
- The abstract is informative and includes methods and key inference claims.
- The narrative arc is generally coherent: motivation → data novelty → design → null results → mechanisms → policy implications.

**Areas to improve for top general-interest**
1. **Clarify the estimand early.** Are you estimating the effect of *fee schedule increases* or the effect of *observed payment-per-claim jumps*? Right now you sometimes speak as if you have clean policy rate changes, but your treatment is “detected from payments.” Make this distinction explicit in the Introduction and revisit in the Discussion.
2. **Magnitude interpretation could be tighter.** You say you can “rule out large positive supply responses” with CI [−0.50, 0.37]. That still allows a ~45% increase in levels at the upper end (exp(0.37)−1). You should translate CIs into level effects for a typical state and discuss whether that is policy-relevant.
3. **Avoid over-claiming exogeneity from ARPA.** ARPA provides a common funding shock, but states may choose timing/magnitude in response to local conditions. Your ARPA-only subsample is a good step; still, use more cautious language unless you can show timing is orthogonal to pre-trends or predicted declines.

Tables are mostly self-contained and well-noted. Consider adding a short “data and treatment definition” note directly under main results tables, since the treatment definition is unusual.

---

# 6. CONSTRUCTIVE SUGGESTIONS (to increase impact)

## 6.1 Make treatment timing externally grounded (highest priority)
As noted, the biggest credibility gain would come from **external policy coding** and a “first-stage” validation in the T‑MSIS rates. A top-journal version should ideally have:
- a dataset of policy effective dates (fee schedule changes / SPA approvals / ARPA plan implementation),
- your payment-per-claim detection as a measurement check (not the sole definition).

## 6.2 Add a triple-difference / within-state negative-control design
Right now you use E/M codes as placebo across states, but you could do something stronger:

- Construct within-state outcomes for:
  1) personal care codes (treated service),
  2) a “nearby” HCBS service category plausibly not targeted by the rate increase (or targeted less),
  3) E/M codes (far placebo).

Then estimate a **DDD**:
\[
(Y^{PC}_{st} - Y^{PlaceboSvc}_{st}) = \alpha_s + \gamma_t + \beta PostTreat_{st} + \epsilon_{st}
\]
This reduces concerns about state-level reporting shocks in T‑MSIS that simultaneously affect rates and counts.

## 6.3 Exploit intensity more convincingly
Your dose-response regression is potentially informative but currently underdeveloped and (by your own admission) confounded by endogeneity (states with crises raise rates more).

Possible approaches:
- Use ARPA formula-driven predicted funds (based on baseline HCBS spending) as an instrument for rate increase magnitude, if feasible.
- Or at least show dose-response within ARPA-only states and control for pre-ARPA trends/levels.

## 6.4 Revisit outcome measurement: units/hours, entry/exit, and churn
- Compute **entry and exit** counts of billing NPIs each month; estimate effects on entry and exit separately. A null on levels could mask offsetting changes.
- If possible, approximate **hours** using 15-minute units for T1019/S5125 (but be careful with per diem codes). Even focusing on T1019-only outcomes could provide a cleaner “quantity of care delivered” measure than claims counts.

## 6.5 Heterogeneity that speaks to policy
To increase general-interest appeal, focus heterogeneity on:
- baseline wage levels / minimum wage changes (interaction with state minimum wage),
- urban vs rural (if you can proxy via NPPES ZIP),
- baseline provider concentration (monopsony angle),
- managed care penetration.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Important policy question with timely relevance (ARPA and HCBS workforce crisis).
- Novel, high-frequency, near-universe administrative data source.
- Good statistical hygiene: SEs, CIs, WCB p-values, modern staggered DiD estimators, placebo and sensitivity checks.
- Transparent discussion of limitations and mechanisms.

### Critical weaknesses
1. **Treatment definition endogeneity/measurement**: adoption dates inferred from the same payment data used to measure outcomes; composition/reporting changes could drive “rate jumps.”
2. **State assignment via NPPES**: plausible but needs stronger validation and robustness.
3. **Control group contamination**: “never-treated” may still have meaningful (sub-threshold or temporary) payment changes or other workforce policies.
4. **Outcome interpretability**: NPI counts are an imperfect proxy for labor supply; more direct extensive/intensive margins (entry/exit, hours) would strengthen interpretation.

### Specific, actionable improvements
- Rebuild the main analysis around externally documented policy rate changes (at least for ARPA-era states), using T‑MSIS detection as validation.
- Provide stronger diagnostics around state assignment and cross-state billing.
- Add DDD or within-state placebo service comparisons to mitigate reporting/composition shocks.
- Expand outcomes to entry/exit and (if possible) units/hours.

Given the promise and the fact that many issues are addressable with additional data work and reframing, this is not a rejection. But it is beyond a minor revision for a top outlet because the central identification concern (endogenous treatment timing from outcomes data) must be more decisively resolved.

DECISION: MAJOR REVISION